[go: up one dir, main page]

DE69632667D1 - CTLA4-Mutantmoleküle und deren Verwendung - Google Patents

CTLA4-Mutantmoleküle und deren Verwendung

Info

Publication number
DE69632667D1
DE69632667D1 DE69632667T DE69632667T DE69632667D1 DE 69632667 D1 DE69632667 D1 DE 69632667D1 DE 69632667 T DE69632667 T DE 69632667T DE 69632667 T DE69632667 T DE 69632667T DE 69632667 D1 DE69632667 D1 DE 69632667D1
Authority
DE
Germany
Prior art keywords
ctla4 mutant
molecules
mutant molecules
soluble
interactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69632667T
Other languages
English (en)
Other versions
DE69632667T2 (de
Inventor
Peter S Linsley
Jeffrey A Ledbetter
Robert Peach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DE69632667D1 publication Critical patent/DE69632667D1/de
Publication of DE69632667T2 publication Critical patent/DE69632667T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69632667T 1995-07-21 1996-07-19 CTLA4-Mutantmoleküle und deren Verwendung Expired - Lifetime DE69632667T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/505,058 US5773253A (en) 1993-01-22 1995-07-21 MYPPPY variants of CTL A4 and uses thereof
US505058 1995-07-21

Publications (2)

Publication Number Publication Date
DE69632667D1 true DE69632667D1 (de) 2004-07-15
DE69632667T2 DE69632667T2 (de) 2005-06-16

Family

ID=24008824

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69632667T Expired - Lifetime DE69632667T2 (de) 1995-07-21 1996-07-19 CTLA4-Mutantmoleküle und deren Verwendung

Country Status (11)

Country Link
US (1) US5773253A (de)
EP (1) EP0757099B1 (de)
JP (1) JP3808553B2 (de)
AT (1) ATE268818T1 (de)
AU (1) AU696664B2 (de)
CA (1) CA2181394C (de)
DE (1) DE69632667T2 (de)
ES (1) ES2223061T3 (de)
IL (1) IL118890A (de)
MX (1) MX9602879A (de)
NO (1) NO317836B1 (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685941B1 (en) * 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6887471B1 (en) * 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
US20060034844A1 (en) * 1996-12-04 2006-02-16 The Regents Of The University Of California Stimulation of T cells against self antigens using CTLA-4 blocking agents
AU735459B2 (en) 1997-01-30 2001-07-12 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
US20030219863A1 (en) * 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
AU743939B2 (en) * 1997-06-12 2002-02-07 Laboratoires Serono Sa CD28/CTLA-4 inhibiting peptidomimetics, pharmaceutical compositions thereof, and method of using same
WO1999015552A1 (en) * 1997-09-19 1999-04-01 Yoshitomi Pharmaceutical Industries, Ltd. Oligopeptide compounds
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
EP0947582A1 (de) * 1998-03-31 1999-10-06 Innogenetics N.V. Eine Polypeptidstruktur zur Verwendung als Gerüst
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6800457B2 (en) * 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
HRP20010551B1 (hr) * 1998-12-23 2013-05-31 Pfizer Inc. Humana monoklonalna antitijela za ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
WO2000060070A1 (en) * 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2589418A1 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
FR2801106B1 (fr) * 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CA2411962A1 (en) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion
SK287940B6 (sk) 2000-07-03 2012-05-03 Bristol-Myers Squibb Company Soluble CTLA4 fusion molecule, pharmaceutical composition comprising thereof and its use
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
AU2002228610A1 (en) * 2000-11-22 2002-06-03 The Ohio State University Agents for blocking t cell mediated immune reactions
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002243905B2 (en) * 2001-01-26 2007-11-08 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
MXPA03010568A (es) 2001-05-23 2005-03-07 Squibb Bristol Myers Co Metodos para proteger trasplantes alogenicos de celulas de isletas usando moleculas mutantes ctla4 solubles.
US20030086940A1 (en) * 2001-08-10 2003-05-08 Cristina Costa Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
SI1503794T1 (sl) * 2002-04-12 2012-09-28 Medarex Inc Postopek zdravljenja z uporabo ctla-4 antiteles
KR20050007375A (ko) * 2002-05-02 2005-01-17 유니버시티 오브 코네티컷 헬스 센터 항체 치료의 효능을 개선하기 위한 열 충격 단백질의 사용
JP4541157B2 (ja) * 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
PT1576182E (pt) 2002-12-23 2011-01-21 Bristol Myers Squibb Co Optimizador da qualidade do produto em processos de cultura celular de mamíferos destinados à produção de proteínas
MXPA05007019A (es) * 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
WO2005014612A1 (en) * 2003-07-09 2005-02-17 The Brigham And Women's Hospital, Inc. Novel splice variant of ctla-4
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
KR101235484B1 (ko) * 2005-04-06 2013-02-22 브리스톨-마이어스 스큅 컴퍼니 가용성 ｃｔｌａ4 돌연변이체 분자를 이용하여 이식편이식과 연관된 면역 장애를 치료하는 방법
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
KR101398713B1 (ko) * 2005-12-20 2014-06-12 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US7528111B2 (en) * 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
MX363905B (es) 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
EP2222697B1 (de) * 2007-11-01 2012-12-05 Perseid Therapeutics LLC Immunosuppressive polypeptide und nukleinsäuren
NZ621443A (en) * 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
EP3372617B1 (de) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Bindungsfusionsproteine, bindungsfusionsproteinarzneimittelkonjugate, xten-arzneimittelkonjugate sowie verfahren zur herstellung und verwendung davon
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
JP2018512856A (ja) 2015-04-17 2018-05-24 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能な親和性を有する免疫調節タンパク質
EP3350206A1 (de) * 2015-09-14 2018-07-25 Alpine Immune Sciences, Inc. Abstimmbarer variante immunglobulin-superfamilie-domänen und manipulierte zelltherapie
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
JP7527758B2 (ja) 2016-04-15 2024-08-05 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質およびその使用
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
MX2019010887A (es) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
KR20250020681A (ko) 2017-10-10 2025-02-11 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
TWI899046B (zh) 2017-10-18 2025-10-01 美商艾爾潘免疫科學有限公司 變異型icos 配位體免疫調節蛋白及相關組合物及方法
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
AU2019372675A1 (en) * 2018-11-02 2021-02-04 Beijing Vdjbio Co., Ltd. Modified CTLA4 and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA2003455C (en) * 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
US5770197A (en) * 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE122007000078I2 (de) * 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US6090914A (en) * 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
AU7107794A (en) * 1993-06-10 1995-01-03 Regents Of The University Of Michigan, The Cd28 pathway immunosuppression

Also Published As

Publication number Publication date
DE69632667T2 (de) 2005-06-16
JPH09202800A (ja) 1997-08-05
AU696664B2 (en) 1998-09-17
IL118890A (en) 2005-08-31
JP3808553B2 (ja) 2006-08-16
NO963018D0 (no) 1996-07-19
NO963018L (no) 1997-01-22
AU6059096A (en) 1997-01-30
ES2223061T3 (es) 2005-02-16
MX9602879A (es) 1997-06-28
EP0757099A2 (de) 1997-02-05
EP0757099B1 (de) 2004-06-09
EP0757099A3 (de) 1999-05-26
US5773253A (en) 1998-06-30
ATE268818T1 (de) 2004-06-15
NO317836B1 (no) 2004-12-20
IL118890A0 (en) 1996-10-31
CA2181394A1 (en) 1997-01-22
CA2181394C (en) 2010-11-02

Similar Documents

Publication Publication Date Title
DE69632667D1 (de) CTLA4-Mutantmoleküle und deren Verwendung
ATE170562T1 (de) Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen
DK0613944T3 (da) Fremgangsmåder til regulering af immunresponset under anvendelse af CTLA4-bindende molekyler og IL4-bindende molekyler
DE69724428D1 (de) Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren
NO961115D0 (no) Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser
AU3900589A (en) Antigenic constructs of major histocompatibility complex class 1 antigens with specific carrier molecules, the preparation and use thereof
AU4690897A (en) Method of preparing a monoclonal antibody, monoclonal antibody, a pharmaceutical composition and a diagnostic reagent
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
DE69232945D1 (de) BLUTPLAETTCHEN-GPIIIa P1A1 und -P1A2-EPITOPE, IHRE HERSTELLUNG UND VERWENDUNG
DE69230762D1 (de) Icams konstante domäne wasserlöslichen fusionsproteine, immunoglobulin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition